Viamet to Present Interim RENOVATE Results at the American Podiatric Medical Association 2016 Annual Meeting

Viamet Pharmaceuticals, Inc. today announced that data from a planned interim analysis of RENOVATE, a Phase 2b clinical trial of VT-1161 in onychomycosis of the toenail, will be presented at the American Podiatric Medical Association 2016 Annual Meeting, to be held July 14-17, in Philadelphia. VT-1161, the company’s lead product candidate, is a highly potent and selective orally-administered inhibitor of fungal CYP51.